ATE248157T1 - Verbindungen und verfahren zur modulation von estrogen rezeptoren - Google Patents

Verbindungen und verfahren zur modulation von estrogen rezeptoren

Info

Publication number
ATE248157T1
ATE248157T1 AT99968578T AT99968578T ATE248157T1 AT E248157 T1 ATE248157 T1 AT E248157T1 AT 99968578 T AT99968578 T AT 99968578T AT 99968578 T AT99968578 T AT 99968578T AT E248157 T1 ATE248157 T1 AT E248157T1
Authority
AT
Austria
Prior art keywords
methods
disclosed
compounds
same
modulating
Prior art date
Application number
AT99968578T
Other languages
English (en)
Inventor
Bernd M Stein
David W Anderson
Leah M Gayo
May S Sutherland
Mary Doubleday
Graziella I Shevlin
Adam Kois
Sak Khammungkhune
Ravi Kumar Jalluri
Shripad S Bhagwat
Jeffrey A Mckie
Original Assignee
Signal Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Inc filed Critical Signal Pharm Inc
Application granted granted Critical
Publication of ATE248157T1 publication Critical patent/ATE248157T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
AT99968578T 1998-12-30 1999-12-30 Verbindungen und verfahren zur modulation von estrogen rezeptoren ATE248157T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11447298P 1998-12-30 1998-12-30
PCT/US1999/031290 WO2000039120A2 (en) 1998-12-30 1999-12-30 Compounds and methods for modulation of estrogen receptors

Publications (1)

Publication Number Publication Date
ATE248157T1 true ATE248157T1 (de) 2003-09-15

Family

ID=22355427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968578T ATE248157T1 (de) 1998-12-30 1999-12-30 Verbindungen und verfahren zur modulation von estrogen rezeptoren

Country Status (14)

Country Link
EP (1) EP1140889B1 (de)
JP (1) JP2002533456A (de)
KR (1) KR100615757B1 (de)
CN (2) CN100339374C (de)
AT (1) ATE248157T1 (de)
AU (1) AU765159B2 (de)
CA (1) CA2356986A1 (de)
DE (1) DE69910830T2 (de)
DK (1) DK1140889T3 (de)
ES (1) ES2207982T3 (de)
HK (1) HK1041258B (de)
IL (2) IL144003A0 (de)
PT (1) PT1140889E (de)
WO (1) WO2000039120A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877897A (en) 1993-02-26 1999-03-02 Donnelly Corporation Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array
US6822563B2 (en) 1997-09-22 2004-11-23 Donnelly Corporation Vehicle imaging system with accessory control
US7655894B2 (en) 1996-03-25 2010-02-02 Donnelly Corporation Vehicular image sensing system
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2003521468A (ja) 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ, インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
KR20020075388A (ko) * 1999-12-30 2002-10-04 시그널 파머슈티컬스 인크 에스트로겐 수용체의 조절 화합물 및 조절 방법
EP1177787A3 (de) * 2000-07-28 2003-09-10 Pfizer Products Inc. Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Katarakt
HUP0401018A3 (en) 2001-01-24 2007-05-29 Chiesi Farma Spa 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
ES2236056T3 (es) * 2001-01-24 2005-07-16 Chiesi Farmaceutici S.P.A. Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
EP1281710A1 (de) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. 2H-1-Benzopyran derivat, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
JP4358515B2 (ja) * 2001-04-10 2009-11-04 タカラバイオ株式会社 治療剤
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2003239155B2 (en) * 2002-04-19 2008-12-04 Novartis Ag Benzopyranone compounds, compositions thereof, and methods of treatment therewith
AU2003225228A1 (en) 2002-05-03 2003-11-17 Donnelly Corporation Object detection system for vehicle
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
FR2849653B1 (fr) * 2003-01-08 2006-08-25 B F B Etudes Et Rech S Experim Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant
CN1890235A (zh) 2003-09-15 2007-01-03 西格诺药品有限公司 苯并吡喃酮化合物,其组合物以及用其进行治疗的方法
US7526103B2 (en) 2004-04-15 2009-04-28 Donnelly Corporation Imaging system for vehicle
WO2006078834A1 (en) * 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
EP1899316A1 (de) * 2005-06-24 2008-03-19 Signal Pharmaceuticals LLC Benzopyranonverbindungen zur behandlung von krebs
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
EP1860104A1 (de) * 2006-05-22 2007-11-28 Aptanomics Von 3-Arylcoumarin oder 3-Arylchinolin-2-on abgeleitete antiproliferative Verbindungen und ihre Verwendung
CN101200460B (zh) * 2007-11-19 2010-06-16 北京珅奥基医药科技有限公司 二氢苯并吡喃酮类化合物及其用途
CN105541810B (zh) * 2016-03-04 2019-05-17 南京工业大学 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用
CN105801543B (zh) * 2016-04-18 2019-08-02 中国药科大学 4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN105801544A (zh) * 2016-04-18 2016-07-27 中国药科大学 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN112426420B (zh) * 2020-12-01 2021-12-28 浙江大学 香豆素-二硫代氨基甲酸酯衍生物在制备抗肿瘤药物中的应用
CN112645922B (zh) * 2020-12-24 2022-01-07 中国人民解放军空军军医大学 香豆素类化合物、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857401A (en) * 1956-12-20 1958-10-21 Searle & Co Acetylated coumarin derivatives
DE4323409A1 (de) * 1993-07-13 1995-01-19 Boehringer Mannheim Gmbh Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel
JPH10513470A (ja) * 1995-02-06 1998-12-22 イーライ・リリー・アンド・カンパニー Il−6の効果を阻害する方法
ES2188908T3 (es) * 1996-10-28 2003-07-01 Novo Nordisk As Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
ZA979645B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
JP2001502711A (ja) * 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は治療において有用な新規のシス―3、4―クロマン誘導体
ZA979644B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
IL129622A0 (en) * 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
EP0937059A1 (de) * 1996-10-28 1999-08-25 Novo Nordisk A/S $i(TRANS)-3,4-CHROMANDERIVATE ZUR VORBEUGUNG ODER BEHANDLUNGVON OESTROGENBEZOGENEN KRANKHEITEN ODER SYNDROMEN

Also Published As

Publication number Publication date
KR100615757B1 (ko) 2006-08-25
HK1075893A1 (zh) 2005-12-30
CN1597677A (zh) 2005-03-23
CN1155589C (zh) 2004-06-30
ES2207982T3 (es) 2004-06-01
DK1140889T3 (da) 2003-12-22
IL144003A0 (en) 2002-04-21
KR20010101346A (ko) 2001-11-14
WO2000039120A2 (en) 2000-07-06
JP2002533456A (ja) 2002-10-08
DE69910830T2 (de) 2004-06-17
CN1337958A (zh) 2002-02-27
CA2356986A1 (en) 2000-07-06
IL144003A (en) 2006-07-05
DE69910830D1 (de) 2003-10-02
EP1140889B1 (de) 2003-08-27
AU2597000A (en) 2000-07-31
AU765159B2 (en) 2003-09-11
HK1041258A1 (en) 2002-07-05
CN100339374C (zh) 2007-09-26
PT1140889E (pt) 2004-01-30
EP1140889A2 (de) 2001-10-10
WO2000039120A3 (en) 2000-10-26
HK1041258B (en) 2003-12-12

Similar Documents

Publication Publication Date Title
ATE248157T1 (de) Verbindungen und verfahren zur modulation von estrogen rezeptoren
ATE289300T1 (de) Verbindungen und verfahren zur modulation von estrogen rezeptoren
WO2000055137A8 (en) Compounds and methods for modulation of estrogen receptors
ATE355279T1 (de) Pyrazole als modulatoren des östrogenrezeptors
Lecanda et al. Gap junctional communication modulates gene expression in osteoblastic cells
ES2172579T3 (es) Agonistas/antagonistas de estrogenos.
AU5467699A (en) Substituted isoxazole as estrogen receptor modulators
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
DE69838177D1 (de) Androgensyntheseinhibitoren
CY1115317T1 (el) Εκλεκτικος ρυθμιστης οιστρογονικου υποδοχεα σε συνδυασμο με δεϋδροεπιανδροστερονη (dhea) ή αναλογα
ATE148331T1 (de) Vorrichtung zum produzieren von knochenzement zur fixierung von prothesen
ATE292468T1 (de) Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie
DE69603827D1 (de) Waisen-rezeptor
TR200003377T2 (tr) Estrojenler ile bütünleşik 2-fenil-1-[4-(2-aminoetoksi)benzil]-indol
NO20000579L (no) Heparin-bindende vekstfaktor (HBGF) -polypeptider
BR0110087A (pt) Compostos para modular proliferação celular
NO984631D0 (no) <alfa>1-Adrenerge reseptor-antagonister
Friedman The Estradiol-Dihydrotestosterone model of prostate cancer
DE69720620D1 (de) 8-Substituierte B-nor-6-Thiaequilin Verbindungen als selektiven Östrogenrezeptormodulatoren
DK1196428T3 (da) 11-beta-aryl-17,17-spirothiolan-substituerede steroider
ES2155911T3 (es) Derivados de alcanfor como nuevos odorantes.
MY137604A (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith
Charnock-Jones et al. Vascular endothelial growth factor and corpus luteum angiogenesis
Meyers The role of hormone receptors in estrogen activity is questionable
KR980000154A (ko) 홍화씨를 주재로한 신규한 식품소재

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140889

Country of ref document: EP

REN Ceased due to non-payment of the annual fee